Trial Profile
An Open-Label, Multiple Ascending-Dose, Study to Evaluate the Pharmacokinetic Profile and D2 Occupancy of HP-3070 Patch in Subjects Diagnosed with Schizophrenia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Mar 2021
Price :
$35
*
At a glance
- Drugs Asenapine (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Pharmacokinetics
- Acronyms Study 3
- Sponsors Hisamitsu Pharmaceutical
- 12 Mar 2021 Results from Three randomized open label studies published in the Journal of Clinical Psychopharmacology
- 18 Nov 2016 Status changed from recruiting to completed.
- 02 Mar 2016 New trial record